| Dr Mahendra Gunapooti, MD | |
|
261 Dunn Rd, Florissant, MO 63031-7928 | |
| (314) 450-8810 | |
| (314) 678-0583 |
| Full Name | Dr Mahendra Gunapooti |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 30 Years |
| Location | 261 Dunn Rd, Florissant, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114034931 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 2004022990 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gateway Regional Medical Center | Granite city, IL | Hospital |
| Christian Hospital Northeast | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Interventional Pain Management | 3779532858 | 5 |
News Archive
Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.
Cancer researchers at University College Dublin have led the development of a new test which uses urine to detect prostate cancer. Studies have so far shown the test to be 70% more specific for prostate cancer compared to the blood test currently used by doctors.
About one decade after its first benefit assessment of negative pressure wound therapy, the German Institute for Quality and Efficiency in Health Care is reassessing this treatment method. However, then as now, its benefit and harm are unclear.
An emerging form of so-called "flesh-eating bacteria" is caused by a strain that is resistant to standard first-line antibiotics. The same type of bacteria, methicillin-resistant Staphylococcus aureus (MRSA) is causing record numbers of less-serious skin infections in children and also is emerging as a cause of pneumonia, which can be deadly
› Verified 7 days ago
| Entity Name | Interventional Pain Management |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710018247 PECOS PAC ID: 3779532858 Enrollment ID: O20050228000154 |
News Archive
Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.
Cancer researchers at University College Dublin have led the development of a new test which uses urine to detect prostate cancer. Studies have so far shown the test to be 70% more specific for prostate cancer compared to the blood test currently used by doctors.
About one decade after its first benefit assessment of negative pressure wound therapy, the German Institute for Quality and Efficiency in Health Care is reassessing this treatment method. However, then as now, its benefit and harm are unclear.
An emerging form of so-called "flesh-eating bacteria" is caused by a strain that is resistant to standard first-line antibiotics. The same type of bacteria, methicillin-resistant Staphylococcus aureus (MRSA) is causing record numbers of less-serious skin infections in children and also is emerging as a cause of pneumonia, which can be deadly
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mahendra Gunapooti, MD Po Box 650, Edwardsville, IL 62025-0650 Ph: (314) 450-8810 | Dr Mahendra Gunapooti, MD 261 Dunn Rd, Florissant, MO 63031-7928 Ph: (314) 450-8810 |
News Archive
Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.
Cancer researchers at University College Dublin have led the development of a new test which uses urine to detect prostate cancer. Studies have so far shown the test to be 70% more specific for prostate cancer compared to the blood test currently used by doctors.
About one decade after its first benefit assessment of negative pressure wound therapy, the German Institute for Quality and Efficiency in Health Care is reassessing this treatment method. However, then as now, its benefit and harm are unclear.
An emerging form of so-called "flesh-eating bacteria" is caused by a strain that is resistant to standard first-line antibiotics. The same type of bacteria, methicillin-resistant Staphylococcus aureus (MRSA) is causing record numbers of less-serious skin infections in children and also is emerging as a cause of pneumonia, which can be deadly
› Verified 7 days ago
Megan Nicole Breckenkamp, PA-C Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 261 Dunn Rd, Florissant, MO 63031 Phone: 314-254-6920 |